From www.bloodjournal.org by guest on June 16, 2017. For personal use only.
2524
BLOOD, 3 OCTOBER 2013 x VOLUME 122, NUMBER 14
Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib
(SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia
patients with resistance or intolerance to imatinib. Blood. 2011;118(17):4567-4576.
On pages 4568, 4572, 4574, and 4576 of the 27 October 2011 issue, there are errors in the text. On page 4568 in the “Study design”
section, in the second sentence of the second paragraph, the article incorrectly states that “The primary end point was the MCyR rate at 24
weeks in patients with CP imatinib-resistant or imatinib-intolerant CML and no previous TKI exposure other than imatinib.” The sentence
should have read, “The primary end point was the MCyR rate at 24 weeks in patients with CP imatinib-resistant CML and no previous
TKI exposure other than imatinib.” The primary end point only involved imatinib-resistant patients.
On page 4572, in the “Safety” section, in the third sentence of the second paragraph, the article incorrectly states that “Three patients
resistant to imatinib experienced grade 3 hemorrhagic AEs (any causality); all events were in the context of concurrent thrombocytopenia.”
A review of the source data tables revealed that only 1 of the 3 patients had concurrent thrombocytopenia; the other 2 did not. The sentence
should have read, “Three patients resistant to imatinib experienced grade 3 hemorrhagic AEs (any causality); one of which occurred in the
context of concurrent thrombocytopenia.”
An additional sentence in the text also need to be corrected based on this error. Accordingly, the incorrect statement repeats on
page 4574, in the Discussion, in the fourth sentence of the third paragraph, which reads, “Three patients reported grade 3/4
hemorrhagic events (with concurrent thrombocytopenia) that subsequently resolved.” The sentence should have read, “Three
patients reported grade 3/4 hemorrhagic events; 1 of whom had concurrent thrombocytopenia that subsequently resolved.” On page
4574, in the Discussion, the seventh sentence of the third paragraph reads, “Consistent with these observations, bleeding has been
reported in 40% of patients treated with dasatinib, 10% of which were grade 3/4,25,28 whereas in contrast only 5% of patients (1%
with grade 3) experienced hemorrhagic events in this study.” The sentence should have read, “Treatment-related bleeding has been
reported in 11% to 16% (all grades) of dasatinib patients,28 whereas in this study, 2% (5 of 288) of patients with CML in CP
receiving bosutinib as second-line therapy experienced treatment-related bleeding events.” Note that the reference for bleeding with
dasatinib has been changed to the more appropriate Shah article, because the original reference 28 from Brave et al included
patients with both CP and AP CML, as well as ALL (the relevant bleeding data appear in Table 2 in the supplemental Appendix of
the Shah article).
On page 4576, in References, reference 28 cites Brave M, Goodman V, Kaminskas E, et al. Sprycel for chronic myeloid leukemia
and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer
Res. 2008;14(2):352-359. Reference 28 should have cited Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of
BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in
chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010;95(2):
232-240.
© 2013 by The American Society of Hematology
McClain KL. Are all mutant SNARES equal? Blood. 2012;119(25):5944-5945.
On page 5944 in the 21 June 2012 issue, there is an error in the fifth sentence of the second paragraph of the Inside Blood commentary.
During copyediting, the abbreviation “NK cells” was expanded incorrectly to “national” instead of “natural” killer cells. The sentence
reads, “In an earlier report on FHL5 patients, Meeths et al evaluated 11 patients with STXBP2 mutations and showed that stimulation of
the lymphocytes with IL-2 rescued the national killer cell functional defects.” The sentence should have read, “In an earlier report on
FHL5 patients, Meeths et al evaluated 11 patients with STXBP2 mutations and showed that stimulation of the lymphocytes with IL-2
rescued the natural killer cell functional defects.” The error has been corrected in the online version, which now differs from the print
version.
© 2013 by The American Society of Hematology
From www.bloodjournal.org by guest on June 16, 2017. For personal use only.
2013 122: 2524
doi:10.1182/blood-2013-08-524256
Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of
bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive
chronic myeloid leukemia patients with resistance or intolerance to
imatinib. Blood. 2011;118(17):4567-4576
Updated information and services can be found at:
http://www.bloodjournal.org/content/122/14/2524.2.full.html
Articles on similar topics can be found in the following Blood collections
Free Research Articles (4527 articles)
Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests
Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints
Information about subscriptions and ASH membership may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society
of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.
Copyright 2011 by The American Society of Hematology; all rights reserved.